Please note our product candidate is not yet available or approved for use.
We are developing our products in a tightly regulated environment of clinical studies that are reviewed and approved by the national respective authorities to establish a maximum safety level for patients. Currently, therefore, access to our investigational cell therapy is limited to patients meeting the eligibility criteria of our clinical trials.
Our lead product candidate ATIR101 is currently being evaluated in the following clinical trial:
Clinical trial: CR-AIR-009
A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor and adjunctive treatment with ATIR101, a T-lymphocyte enriched eukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclphosphamide in patients with a hematologic malignancy (HATCY study).
If you are a medical professional and would like information about becoming an investigator for one of our clinical trials, please contact email@example.com